People
Daisuke Morishita
Daisuke Morishita, Ph.D. (University of Tokyo), specializes in drug discovery science and oncology. After conducting drug discovery research at Takeda and Harvard, he co-founded Chordia Therapeutics in 2017 and played a pivotal role in the company’s listing on the Tokyo Stock Exchange Growth Market. He has been recognized with major national honors for venture creation and innovation in 2022 and 2024. In academia, he concurrently serves as a Visiting Professor at Nagoya City University, Kumamoto University, and Oita University, and as a Councilor of a leading Japanese oncology society. LinkedIn Newton Biocapital publicly documents this person as Venture Partner. The affiliation is scoped to the published role, with no personal cash investment inferred.
Roles
Venture Partner